Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)
Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI) supports organizations studying diagnostic-guided treatment in adults to assess timely therapy and clinical effectiveness.
Funder: Pfizer Inc.
Due Dates: November 25, 2026, at 23:59 EST (Submission) | February 17, 2027 (Anticipated notification) | June 1, 2027 or project start (IRB approval) | June 2027 (Anticipated start) | December 2028 (Anticipated end)
Funding Amounts: Up to $50,000 USD per project for up to 18 months; $100,000 total budget for 2–3 projects
Summary: Supports independent real-world research on rapid diagnostic-guided ATM-AVI treatment and clinical outcomes in adults with CRE or Stenotrophomonas maltophilia infections.
Key Information: Institutions participating in overlapping Pfizer-sponsored or funded ATM-AVI real-world evidence studies are ineligible.
Description
Pfizer’s competitive independent research program funds studies assessing outcomes associated with early and appropriate aztreonam-avibactam (ATM-AVI) use, guided by actionable rapid diagnostic results in real-world clinical settings. The focus is adult patients with suspected or documented infections due to carbapenem-resistant Enterobacterales (CRE) or Stenotrophomonas maltophilia who are treated with ATM-AVI.
Projects must assess how diagnostic workflows affect earlier selection of appropriate therapy, measuring time to appropriate therapy and clinical effectiveness. Measuring diagnostic-guided antibiotic escalation and de-escalation rates and microbiological outcomes is strongly encouraged; health economic outcomes may be added. Pfizer uses an internal review process to select projects. Funded organizations remain responsible for research design, implementation, sponsorship, and conduct; Pfizer must not participate in protocol development, research conduct, or monitoring.
